MHMatthew M. Hsieh

Matthew M. Hsieh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Matthew M. Hsieh has a total of 346 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Characteristics of donor and recipient clonal hematopoiesis in nonmyeloablative transplant for sickle cell disease

    by Lachelle D. Weeks, Donna Neuberg, Emily M. Limerick, Matthew M. Hsieh, Xin Xu, Mariama D. Kabore, Rialnat A. Lawal, Alexis Leonard, Yating Wang, Oswald Phang, et al.

    Sickle cell disease (SCD) is an inherited hemoglobinopathy characterized by chronic hemolytic anemia, painful vaso-occlusive episodes, and end-organ damage. Cellular therapies, including allogeneic hematopoietic cell transplantation (allo-HCT) and gene therapy, are potentially curative treatments for SCD. Cases of myelodysplastic syndrome or acute myeloid leukemia (MDS/AML) occurring after cellular therapy for SCD and reports of an increased relative risk of AML in populations with SCD have raised questions about the association between SCD and clonal hematopoiesis (CH), a recognized precursor state for MDS/AML. We used error-corrected DNA sequencing to detect CH variants at a variant allele fraction >0.0005 in blood samples from 98 individuals with SCD and 72 donor controls without SCD who underwent HCT at the National Institutes of Health or an outside hospital (n = 2) between July 2004 and June 2023. Baseline CH prevalence was similar in recipients and donors; however, recipients with SCD had 3.8-fold higher odds of DNA damage response (DDR)–mutant CH involving TP53, PPM1D, ATM, and CHEK2 compared with donors without SCD. After HCT, the proportion of recipients with SCD with CH increased, driven primarily by mutations in DNMT3A/TET2 and TP53. Post-HCT CH arose from newly emergent variants undetectable at baseline in both recipient and paired donor samples, engrafted donor-derived CH, and persistent recipient CH. All cases of donor-derived CH involved DNMT3A/TET2 mutations, whereas persistent recipient CH involved DDR mutations. Hematologic neoplasms were rare but included 3 cases of fatal TP53-mutant MDS/AML. Larger cohort studies are needed to identify the risk factors for developing DDR-CH and MDS/AML in SCD and to optimize cellular therapy safety in this population.


  • Open Access

    Mixed myeloid chimerism and hemolytic markers after nonmyeloablative HCT for sickle cell disease

    by Zaina Inam, Francis J. Pierciey, Matthew Hsieh, Alexis Leonard, Selami Demirci, John Tisdale


  • Open Access

    Comparative analysis of CRISPR-Cas9, lentiviral transduction, and base editing for sickle cell disease in a murine model

    by Henna Butt, Shruti Sathish, Evan London, Anh Le, Quan Li, Bjorg Gudmundsdottir, Duck-Yeon Lee, Emma V. Burke, Bradley P. Yates, David R. Liu, et al.

    Sickle cell disease (SCD) is a red blood cell disorder caused by a mutation in the β-globin gene, leading to sickle hemoglobin polymerization under low oxygen conditions. Both CRISPR-Cas9 editing and lentiviral transduction have shown promising clinical outcomes, but it remains unclear which approach is superior. Alternatively, new editing tools such as base editing may also be promising and reduce risks of genotoxicity. To compare these approaches, we studied them in an immunocompromised mouse model. We optimized ex vivo conditions in CD34+ hematopoietic stem and progenitor cells (HSPC) and infused edited SCD HSPC into busulfan-conditioned nonirradiated NOD,B6.SCID Il2rγ−/−KitW41/W41 (NBSGW) mice. Ex vivo analysis confirmed successful editing and transduction. At 16 weeks, bone marrow analysis showed similar human CD45+ cell engraftment across all groups (75%-90%). In the competitive transplantation group, there was a lower amount of B-cell lymphoma/leukemia 11A enhancer editing than base editing and lentiviral transduction. A secondary transplantation model yielded similar results. An antisickling assay showed significantly higher red blood cell sickling reduction in the base editing, transduction, and competitive transplantation groups compared to CRISPR-Cas9. In conclusion, although all methods showed therapeutic potential, base editing and lentiviral transduction provided superior outcomes over CRISPR-Cas9–mediated editing in a competitive murine transplantation model.


  • Open Access

    Revaccination Response and Lack of Hepatitis B Reactivation After HCT for Sickle Cell Disease

    by Henna Butt, Neal Jeffries, Triscia Martin, Valeria De Giorgi, Alison Zamora, John F. Tisdale, Matthew M. Hsieh

    Background: Sickle cell disease (SCD) can be cured by hematopoietic cell transplantation (HCT), but patients face increased risk of hepatitis B virus (HBV) reactivation due to immunosuppression. Understanding hepatitis B surface antibody (anti‐HBs) kinetics is essential for optimizing HBV revaccination and posttransplant care. Methods: This post hoc analysis examined HBV immunity, reactivation, and revaccination response in 71 SCD patients who underwent HCT at the National Heart, Lung, and Blood Institute (2008–2021) using alemtuzumab and low‐dose total body irradiation. Results: At baseline, 55% showed HBV immunity (anti‐HBs ≥ 12 mIU/mL). Most patients responded to revaccination regardless of baseline immunity. Post‐HCT revaccination was given to 93%, with 89% completing full series (Heplisav‐B or Engerix‐B). Vaccinated patients had a 67.5% chance of increased anti‐HBs titers between Years 1 and 2, though no significant difference was seen compared to unvaccinated patients ( p = 0.12). No HBV reactivation occurred; two patients with baseline HBcAb and HBsAg positivity showed decreasing HBV DNA levels. Conclusions: Results indicate that HBV immunity can decline post‐HCT, but most patients remain immune, and revaccination is effective. However, some non‐responders—especially those treated with IVIG, rituximab, or prolonged immunosuppression—need further study. Prospective research is needed to optimize revaccination timing and immune monitoring in this high‐risk group. image

  • Open Access

    Two Nonmyeloablative HLA-Matched Related Donor Allogeneic Hematopoietic Cell Transplantation Regimens in Patients with Severe Sickle Cell Disease

    by Zaina Inam, Neal Jeffries, Mary Link, Wynona Coles, Priscilla Pollack, Christina Luckett, Oswald Phang, Elizabeth Harvey, Triscia Martin, Tiffani Farrey, et al.


  • Open Access

    Lipid Levels Increase to the Normal Range After Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease

    by Jackie Queen, Emily Limerick, Neal Jeffries, Matthew M. Hsieh, Robert D. Shamburek, Courtney D. Fitzhugh

  • Open Access

    A machine learning‐based workflow for predicting transplant outcomes in patients with sickle cell disease

    by Haiou Li, Vandana Sachdev, Xin Tian, My‐Le Nguyen, Matthew Hsieh, Courtney Fitzhugh, Emily Limerick, Wynona Coles, Nancy Asomaning, Anna Conrey, et al.

    Summary: Allogeneic haematopoietic cell transplantation (HCT) with HLA‐matched sibling donor remains the most established curative therapeutic option for patients with sickle cell disease (SCD). However, it is not without risks, highlighting the need for a risk stratification system. Utilizing a machine learning (ML) approach that combines clinical and imaging variables, we identified red cell distribution width and renal organ damage as important risk factors for patients undergoing HCT. This ML‐based algorithm, similar to an approach previously reported for predicting mortality in patients with SCD, should be applicable to risk factor discovery in similar studies.


  • Open Access

    Design and Implementation of the Sickle Cell Disease Hematopoietic Cell Transplantation Evaluating Long Term and Late Outcomes Registry (STELLAR) to Compare Long Term Outcomes after Hematopoietic Cell Transplantation to that in Siblings without Sickle Cell Disease and in Non-Transplanted Individuals with Sickle Cell Disease

    by Lakshmanan Krishnamurti, Staci Arnold, Ann Haight, Allistair Abraham, Gregory Guilcher, Tami John, Nitya Bakshi, Shalini Shenoy, Karen Syrjala, Paul Martin, et al.

    Background There are sparse data on long-term and late effects of hematopoietic cell transplantation (HCT) for sickle cell disease (SCD) Objectives To establish an international registry of long-term outcomes post-HCT for SCD and demonstrate the feasibility of recruitment at a single site in the US. Methods The STELLAR registry is designed to enroll SCD patients ≥ 1-year post-HCT, their siblings without SCD, and non-transplanted SCD controls to collect participant self-report of health status and practices using the BMT survivor study surveys, HRQOL using PROMIS 25 or 29, cGVHD using the symptom scale survey, daily pain using an electronic pain diary, economic impact of HCT using the financial hardship survey, and sexual function using PROMIS SexFSv2.0. We also piloted retrieval of clinical data previously submitted to CIBMTR, recorded demographics, height, weight, BP, hip and waist circumference, timed-up-and-go, and handgrip test, and obtained blood for metabolic screening, gonadal function, fertility potential, and biorepository of plasma, serum, RNA, and DNA. Results Among 100 eligible post-HCT patients, we enrolled 72 participants 9-38 (median 17) years age. We also enrolled 19 siblings 5-32 (median10)years age and 28 non-transplanted SCD controls 4-46 (median 22) years age. Of 119 participants, 73 completed 85 sets of surveys and 41 contributed samples to the biorepository. We successfully piloted retrieval of data submitted to CIBMTR and expanded recruitment to seven US, Canada, UK, and Nigeria sites. Conclusions It is feasible to recruit subjects and conduct study procedures for the STELLAR registry of long-term and late effects of HCT for SCD.

  • Open Access

    Increased incidence of hematologic malignancies in SCD after HCT in adults with graft failure and mixed chimerism

    by Rialnat A. Lawal, Devdeep Mukherjee, Emily M. Limerick, Wynona Coles, Matthew M. Hsieh, Laura W. Dillon, Christopher S. Hourigan, Courtney D. Fitzhugh

    Lawal et al report on a 45-fold increase in secondary hematologic malignancy in 120 patients following hematopoietic stem cell transplantation (HSCT) for sickle cell disease (SCD), comparable to what has been reported following gene therapy. Notably, the cohort is enriched for older patients and for haploidentical transplant recipients with mixed chimerism following HSCT. These data further support the idea that pre-existing premalignant myeloid clones undergo clonal selection in the setting of nonmyeloablative HSCT and contribute to secondary malignancy.


  • Open Access

    Sickle Cell Transplantation Evaluation of Long-term and Late Effects Registry (STELLAR) to Compare Long-term Outcomes After Hematopoietic Cell Transplantation to Those in Siblings Without Sickle Cell Disease and in Nontransplanted Individuals With Sickle Cell Disease: Design and Feasibility Study

    by Lakshmanan Krishnamurti, Staci D Arnold, Ann Haight, Allistair Abraham, Gregory Mt Guilcher, Tami John, Nitya Bakshi, Shalini Shenoy, Karen Syrjala, Paul L Martin, et al.

    Background: There are sparse data on the long-term and late effects of hematopoietic cell transplantation (HCT) for sickle cell disease (SCD). Objective: This study aims to establish an international registry of long-term outcomes post-HCT for SCD and demonstrate the feasibility of recruitment at a single site in the United States. Methods: The Sickle Cell Transplantation Evaluation of Long-Term and Late Effects Registry (STELLAR) was designed to enroll patients with SCD ≥1 year post-HCT, their siblings without SCD, and nontransplanted controls with SCD to collect web-based participant self-reports of health status and practices by using the Bone Marrow Transplant Survivor Study (BMTSS) surveys, health-related quality of life (HRQOL) using the Patient-Reported Outcomes Measurement Information System (PROMIS) Pediatric Profile-25 or Pediatric Profile-29 survey, chronic graft-versus-host disease (cGVHD) using the symptom scale survey, daily pain using an electronic pain diary, the economic impact of HCT using the financial hardship survey, sexual function using the PROMIS Sexual Function SexFSv2.0 survey, and economic productivity using the American Time Use Survey (ATUS). We also piloted retrieval of clinical data previously submitted to the Center for International Blood and Marrow Transplant Research (CIBMTR); recorded demographics, height, weight, blood pressure, waist and hip circumferences, timed up and go (TUG) test, and handgrip test; and obtained blood for metabolic screening, gonadal function, fertility potential, and biorepository of plasma, serum, RNA, and DNA. Results: Of 100 eligible post-HCT patients, we enrolled 72 (72%) participants aged 9-38 (median 17) years. We also enrolled 19 siblings aged 5-32 (median 10) years and 28 nontransplanted controls with SCD aged 4-46 (median 22) years. Of the total 119 participants, 73 (61%) completed 85 sets of surveys and 41 (35%) contributed samples to the biorepository. We completed ATUS interviews of 28 (24%) participants. We successfully piloted retrieval of data submitted to the CIBMTR and expanded recruitment to multiple sites in the United States, Canada, the United Kingdom, and Nigeria. Conclusions: It is feasible to recruit subjects and conduct study procedures for STELLAR in order to determine the long-term and late effects of HCT for SCD. International Registered Report Identifier (IRRID): DERR1-10.2196/36780